COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF Russian patent published in 2024 - IPC C07D401/14 C07D471/10 C07D405/14 A61K31/513 A61P9/00 A61P25/28 A61P31/00 A61P35/00 A61P37/00 A61P3/00 A61P7/00 A61P19/08 A61P31/12 

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to pharmacological preparations, namely to a compound of formula I, which is PTM-L-ULM. At the same time ULM has structure ULM-1, where in ULM-1: X'' is CH or N; Y'' is N; Q₁, Q₂, Q₃, Q₄ and Q₅ each independently represents CR₃''; R₃'' each independently represents hydrogen, halogen, C1-C6 alkyl, -O(C1-C6 alkyl); and alkyl is optionally substituted with 1–3 groups independently selected from halogen; m'' is equal to 2; R₁'' each independently represents hydrogen; R₂'' is hydrogen or C1-C6 alkyl, C1-C6 alkyl is optionally substituted with 1 group selected from -O-(C=O)-(C1-C6 alkyl); PTM is PTM-71, where in PTM-71: ring A is 6-member heteroaryl; R_d each independently represents hydrogen, halogen or C1-C6 alkyl; and alkyl is optionally substituted with one or more groups selected from halogen or hydroxyl; n is 1; R_e is hydrogen; R c is hydrogen, -O-(C1-C6 alkyl), -O-(3–8-membered heterocycloalkyl), C1-C6 alkyl; and alkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from hydroxyl, halogen or -O-(C1-C6 alkyl); R_b is hydrogen, -O-(C1-C6 alkyl) or C1-C6 alkyl; and alkyl is optionally substituted with one or more groups independently selected from hydroxyl or halogen; R_a is hydrogen, 3–8 membered heterocycloalkyl, C3-C8 cycloalkyl; L is-(CH2)_j-, and one or more methylenes in -(CH2)_j- are optionally substituted with a group selected from -NR^3'-, -O-, -C(O)-, -C(O)NR^3'-, -NR^3'C(O)-, C3-C12 cycloalkylene or 3–12-membered heterocycloalkylene containing one or two N heteroatoms; R^3' each independently represents hydrogen or C1-C6 alkyl; j is equal to 3, 4, 5, 6, 7, 8, 9, 10; heteroaryl contains 1 heteroatom selected from N, O; 3–8-membered heterocycloalkyl contains 1 heteroatom selected from N, O. Invention also relates to individual compounds, a pharmaceutical composition based on said compounds and use thereof for treating IRAK4-mediated diseases.

EFFECT: obtaining alternative compounds for treating IRAK4-mediated diseases.

30 cl, 4 tbl, 71 ex